Medicus Pharma CSO awarded 25,000 stock options

Medicus Pharma Ltd. Chief Scientific Officer Brennan Edward J. received a grant of stock options, giving him the right to acquire 25,000 Common Shares.

Rhea-AI Filing Summary

Medicus Pharma Ltd. Chief Scientific Officer Brennan Edward J. received a grant of stock options, giving him the right to acquire 25,000 Common Shares. The options have an exercise price of $0.50 per share and expire on March 27, 2031. Following this award, he holds 25,000 options directly.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Brennan Edward J.

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct)

Key Figures

Option grant size: 25,000 options Exercise price: $0.50 per share Underlying shares: 25,000 Common Shares +3 more

6 metrics

Option grant size 25,000 options Stock Option (right to buy) granted March 30, 2026

Exercise price $0.50 per share Conversion or exercise price for granted options

Underlying shares 25,000 Common Shares Shares issuable upon exercise of the options

Total options after grant 25,000 options Total derivative securities following transaction

Exercise start date March 26, 2027 First exercisable date for the options

Expiration date March 27, 2031 Options lapse if not exercised by this date

Key Terms

Stock Option (right to buy), Common Shares, Grant, award, or other acquisition, derivative

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

derivative financial

"transaction_type: derivative"

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Medicus Pharma (MDCX) report for Brennan Edward J.?

Medicus Pharma reported that Chief Scientific Officer Brennan Edward J. received a stock option grant for 25,000 Common Shares. This award gives him the right to buy shares at a fixed exercise price as part of his compensation package.

How many Medicus Pharma (MDCX) shares are covered by the new option grant?

The new option grant covers 25,000 Common Shares of Medicus Pharma. These options provide future purchase rights rather than immediate share ownership, aligning the executive’s potential upside with the company’s long-term stock performance over the option term.

What is the exercise price of the Medicus Pharma (MDCX) stock options granted?

The granted stock options have an exercise price of $0.50 per Common Share. This means Brennan Edward J. can later buy up to 25,000 shares at $0.50 each, regardless of the market price at the time of exercise.

When do the newly granted Medicus Pharma (MDCX) stock options expire?

The stock options granted to Brennan Edward J. expire on March 27, 2031. If they are not exercised by that date, the right to purchase the 25,000 Common Shares at $0.50 per share will lapse and become void.

Is the Medicus Pharma (MDCX) Form 4 transaction an open-market buy or a compensation grant?

The Form 4 transaction is a compensation-related grant, not an open-market purchase. The filing classifies it as a grant or award acquisition, reflecting options awarded to the Chief Scientific Officer at no cost per option on the transaction date.

How many Medicus Pharma (MDCX) options does Brennan Edward J. hold after this transaction?

After this transaction, Brennan Edward J. holds 25,000 stock options directly. These options each relate to one Common Share, giving him the potential to acquire up to 25,000 shares if he chooses to exercise before expiration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 07:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brennan Edward J.

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W.CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.5	03/30/2026		A		25,000		03/26/2027	03/27/2031	Common Shares	25,000	$0	25,000	D

Explanation of Responses:

	/s/ Raza Bokhari, as Attorney-in-Fact, for Edward J. Brennan	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)